Stories from Lausanne, Villigen, Switzerland

11.10.2018 – 12:00

Debiopharm International SA
Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic product in Oncology

Lausanne, Villigen, Switzerland (ots) - Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, today announced a collaboration to pursue the development of a ...

more

1